EIDD-2801 is an oral bioavailable prodrug of the ribonucleoside analogue EIDD-1931. This compound demonstrates broad-spectrum antiviral activity against influenza virus and various coronaviruses. Molnupiravir has gained significant attention as a potential treatment for COVID-19 and other viral infections.
Originally developed for influenza treatment, Molnupiravir's antiviral properties have shown effectiveness against multiple RNA viruses, including coronaviruses.